Four peptides: GHK-Cu, BPC-157, TB-500 and KPV. It is GLOW-70 with the α-MSH fragment KPV added.

How does KLOW-80 differ from GLOW-70?

By the addition of KPV, which brings an anti-inflammatory mechanism. It is also the component with the thinnest evidence base of the four — essentially one published paper, in mouse colitis models.

Has KLOW-80 been studied?

No published study investigates this four-component combination. All available evidence concerns the individual peptides, tested separately.

Why is a four-component blend hard to evaluate?

Because any observation has four candidate explanations plus every interaction between them, and nothing published separates them. Attribution gets harder much faster than the ingredient list grows.

Is KLOW-80 approved as a medicine?

No, in any jurisdiction, and neither is any of its four components. It is supplied here as a laboratory reagent for in-vitro research only.

Research guides

KLOW-80 blend (GHK-Cu, BPC-157, TB-500, KPV)

Four peptides in one vial, and the attribution problem at its most acute: nothing observed with the mixture can be traced to any single component.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

KLOW-80
Cosmetic & Dermal

KLOW-80 is GLOW-70 with a fourth peptide added. It is the most complex blend in the catalogue and the clearest illustration of why complexity and evidence pull in opposite directions.

What is in the vial

GHK-Cu, BPC-157, TB-500 and KPV — the last being the three-residue tail of α-melanocyte-stimulating hormone, which brings an anti-inflammatory mechanism alongside the repair-associated ones. All four have their own articles.

The attribution problem, at four components

Four active molecules produce four candidate explanations for any observation, six pairwise interactions, four three-way interactions and one four-way. None of these has been studied, and no published work provides a way to separate them.

This is not a rhetorical point. It is the reason multi-component preparations are difficult to evaluate in general, and it applies with full force here.

The added component is the one with the thinnest literature

KPV's evidence base is essentially a single 2008 paper in murine colitis models. It is a clean and interesting result about a fragment that retains α-MSH's anti-inflammatory activity while dropping its pigmentation activity — and it is one paper, in one model, in mice.

So the component that distinguishes KLOW-80 from GLOW-70 is also the component with the least behind it. That is worth knowing before treating the fourth ingredient as an upgrade.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

No published study investigates this combination. Everything known about the contents of this vial comes from work on the individual components, tested separately.
With four active components, any observation made with this vial has four candidate explanations plus six pairwise and five higher-order interactions, none of which has been studied.
KPV, the component that distinguishes this blend from GLOW-70, has an evidence base of essentially one published paper in murine colitis models. It is the thinnest of the four.
No published work establishes a basis for the proportions in which the four are combined.
The individual caveats carry over undiminished: BPC-157's literature concentration in one research group, and TB-500 being a fragment rather than the molecule most of the thymosin β4 literature studied.
No safety study of this combination has been published, and no component has a completed published randomised controlled trial in humans.

Common questions

What is in KLOW-80?: Four peptides: GHK-Cu, BPC-157, TB-500 and KPV. It is GLOW-70 with the α-MSH fragment KPV added.
How does KLOW-80 differ from GLOW-70?: By the addition of KPV, which brings an anti-inflammatory mechanism. It is also the component with the thinnest evidence base of the four — essentially one published paper, in mouse colitis models.
Has KLOW-80 been studied?: No published study investigates this four-component combination. All available evidence concerns the individual peptides, tested separately.
Why is a four-component blend hard to evaluate?: Because any observation has four candidate explanations plus every interaction between them, and nothing published separates them. Attribution gets harder much faster than the ingredient list grows.
Is KLOW-80 approved as a medicine?: No, in any jurisdiction, and neither is any of its four components. It is supplied here as a laboratory reagent for in-vitro research only.

Compounds covered

The reference page for each compound this article discusses.

KLOW-80

GLOW-70 blend (GHK-Cu, BPC-157, TB-500)
Three peptides in one vial and no published study of the three together. What each component's literature covers, and why three components is harder than two.
KPV (alpha-MSH 11-13): what the research says
The three-residue tail of α-MSH keeps the anti-inflammatory activity and drops the pigmentation. What the murine colitis work reported, and how thin it is.
GHK-Cu copper peptide: what the research says
The copper tripeptide GHK-Cu has the strongest published evidence of any repair peptide here, spanning wound models, gene expression and cosmetic dermatology.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides